Mild pain

Company's strategic expansion, based on demand, has generated global presence LINDON, Utah, Sept. 27, 2024 /PRNewswire/ -- TheraLight, LLC, a rapidly growing global leader in light therapy and developer of full body LED technology, is excited to announce that its light therapy beds can now be found in 16 countries, including the United States. A mix of both personal and business clientele, this level of distribution expansion continues to substantiate TheraLight's presence as a subject, thought, research, and overall industry leader. The company's products and services are available in: Australia Austria Bulgaria China Germany Gibraltar Ireland New Delhi Peru Spain New Zealand Switzerland Ukraine United Kingdom United States Uzbekistan "We are thrilled to see TheraLight's technology making a global impact, reaching new countries and diverse communities. Our mission has always been to improve lives through innovation, and this expansion is a testament to the growing recognition of the power of light therapy. We are committed to continuing to provide world-class products that support wellness and recovery, empowering individuals and professionals alike to achieve their health and practice goals," said Justin Vorwaller, COO of TheraLight, LLC. TheraLight full body LED light beds include the company's flagship model, the Theralight 360, along with the TheraLight FIT and TheraLight 360+. The beds utilize red and near-infrared LED lights in up to four wavelengths (633nm, 810nm, 850nm, and 940nm) designed to promote healing in the body and overall wellness. Universities, medical practices, wellness clinics, gyms, and high-end spas use these therapy beds to support wellness in their facilities. The red and near-infrared light used at the specific wavelengths in TheraLight's products has been shown to activate metabolic energy processes in the body and promote ATP production to boost energy transport within cells. Because of this boost to the body's natural processes, red light therapy is used to reduce inflammation and promote the healing of damaged tissue in various applications. Red light therapy is commonly used to treat scarring, wounds, signs of aging, and minor aches and pain from sports injuries, arthritis, and tendonitis. The treatments, which take between three and 20 minutes, are painless and customizable to the individual's needs. Persons should always consult a doctor before starting a new wellness routine or modality. To learn more about TheraLight and red light therapy, please visit: theralight.com. About TheraLight, LLC: TheraLight, LLC is a medical device company and emerging global leader in innovative photomedicine technology. Representing management with over 30 years of experience, TheraLight delivers expertise in design, manufacturing, production, and regulatory compliance. We partner with healthcare professionals to bring the best and newest technology, as well as provide advanced training and support to maximize clinical and financial outcomes. TheraLight was started and is currently led by the founders of Aspen Laser Systems, LLC, (aspenlaser.com). For more information, please visit theralight.com. MEDIA CONTACT: TheraLight, LLC Dante Strom [email protected] 877-782-7736 SOURCE TheraLight, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acetaminophen is considered the safest over-the-counter pain reliever and fever reducer available during pregnancy. Studies have shown that 50%-65% of women in North America and Europe take acetaminophen during pregnancy. A new study explored the relationship between acetaminophen use during pregnancy and language outcomes in early childhood. It found that increasing acetaminophen use was associated with language delays. Acetaminophen is considered the safest over-the-counter pain reliever and fever reducer available during pregnancy. Studies have shown that 50%-65% of women in North America and Europe take acetaminophen during pregnancy. A new study from researchers at the University of Illinois Urbana-Champaign explored the relationship between acetaminophen use during pregnancy and language outcomes in early childhood. It found that increasing acetaminophen use was associated with language delays. The findings are reported in the journal Pediatric Research. Earlier studies have found associations between acetaminophen use during pregnancy and poorer child communication skills. But those studies used measures of language development that were less precise than the methods applied in the current study, said Megan Woodbury, who led the research as a graduate student with U. of I. comparative biosciences professor emerita Susan Schantz. The work was conducted as part of the Illinois Kids Development Study, which explores how environmental exposures in pregnancy and childhood influence child development. Schantz is the IKIDS principal investigator. Woodbury is now a postdoctoral researcher at Northeastern University in Boston. "The previous studies had only asked pregnant people at most once a trimester about their acetaminophen use," Woodbury said. "But with IKIDS, we talked to our participants every four to six weeks during pregnancy and then within 24 hours of the kid's birth, so we had six time points during pregnancy." The language analyses involved 298 2-year-old children who had been followed prenatally, 254 of whom returned for further study at age 3. For the 2-year-olds, the researchers turned to the MacArthur-Bates Communicative Development Inventories, which asks a parent to report on the child's vocabulary, language complexity and the average length of the child's longest three utterances. "We wanted to collect data at that age because it's the period called 'word explosion,' when kids are just adding words every day to their vocabulary," Schantz said. The vocabulary measure asked parents to select words their child had used from a list of 680 words. The parents assessed their child again at 3 years, comparing their language skills to those of their peers. The analysis linked acetaminophen use in the second and third trimesters of pregnancy to modest but significant delays in early language development. "We found that increased use of acetaminophen -- especially during the third trimester -- was associated with smaller vocabulary scores and shorter 'mean length of utterance' at two years," Woodbury said. "At age three, greater acetaminophen use during the third trimester was related to parents ranking their kids as lower than their peers on their language abilities," Schantz said. "That outcome was seen primarily in male children." The most dramatic finding was that each use of acetaminophen in the third trimester of pregnancy was associated with an almost two-word reduction in vocabulary in the 2-year-olds. "This suggests that if a pregnant person took acetaminophen 13 times -- or once per week -- during the third trimester of that pregnancy, their child might express 26 fewer words at age 2 than other children that age," Woodbury said. Fetal brain development occurs throughout pregnancy, but the second and third trimesters are especially critical times, Schantz said. "Hearing is developing in the second trimester, but language development is already starting in the third trimester before the baby is even born," she said. "It's thought that acetaminophen exerts its analgesic effect through the endocannabinoid system, which is also very important for fetal development," Woodbury said. The findings need to be tested in larger studies, the researchers said. Until then, people should not be afraid to take acetaminophen for fever or serious pain and discomfort during pregnancy. Conditions like a very high fever can be dangerous and using a drug like acetaminophen will likely help. "There aren't other options for people to take when they really need them," Schantz said. "But perhaps people should use more caution when turning to the drug to treat minor aches and pains." This work was supported by the Children's Environmental Health and Disease Prevention Research Center funded by the National Institute of Environmental Health Sciences and the U.S. Environmental Protection Agency and the National Institutes of Health Environmental Influences on Child Health Outcomes program.